Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
Jared R. Lowe, Daniel J. Perry, April K. S. Salama, Clayton E. Mathews, Larry G. Moss, Brent A. Hanks
Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 89; DOI: 10.1186/s40425-016-0196-z